The latest

News

Latest news121

Derek Sims, Cornell Mallari, and Terry Hermiston of Coagulant in the lab

Coagulant Therapeutics Announces Publication of In Vivo Data Demonstrating Safety and Efficacy of CT-001 for the Management of Acute Bleeding

Uncontrolled bleeding is the single largest cause of death among individuals ages 1 to 44 years. In fact, 40% of all trauma deaths are a result of blood loss. And yet, on the other side of the spectrum, blood clots can lead to another set of serious health problems. That’s why Coagulant is developing CT-001, a recombinant coagulation factor that circulates in the blood for only 3 minutes. Read post
Beth Zotter holding some kelp

Is Seaweed the Next Big Alternative to Meat?

Smithsonian Magazine covers the emerging sector of foodtech companies, including Bakar Labs tenant Umaro Foods, making delicious products from one of the world's great underused resources: kelp. Umaro CEO Beth Zotter says “[Bacon is] a product notorious for being hard to give up for vegetarians. It’s sort of like the gateway drug that makes people revert back to full-on carnivory." Read post
Little girl touching little boy's face

ResVita Bio receives Rare Pediatric Disease Designation for RVB-001 as a Treatment for Netherton Syndrome

"The physical and emotional challenges of chronic skin diseases are devastating to patients, particularly children" said Amin Zargar, Chief Executive Officer of ResVita Bio. "Newborns with Netherton Syndrome face a severe lifelong disease with few treatment options that offer limited efficacy. We are motivated by the prospect to deliver meaningful improvement in the lives of these patients, and this is a significant step towards the development RVB-001 as a treatment for Netherton Syndrome." Read post
External photo of BBH by Bruce Damonte

Brutalist Former Berkeley Art Museum Transformed Into Modern Life Science Lab

Seismic performance, water intrusion, and acoustic performance, were addressed while bringing the building up to code. Mechanical, electrical, and plumbing infrastructure was overhauled, including the replacement of existing gas service with all-electric systems. This allowed the project to achieve low EUI, operational carbon neutrality, and Net-Zero HVAC water-use, as well as to meet LEED Gold requirements. Read post
Josh Yang of Glyphic Bio in their lab at Bakar Labs

How Berkeley Is Leaning in to the Biotech Boom

"Nowadays, they meet in person at the Bakar BioEnginuity Hub, the recently completed lab and office space that is emblematic of UC Berkeley’s efforts to support bioscience startups. It’s part of a web of startup activity on campus that’s so vast, the university created a website to help people navigate it." Read post
Large group of people mingling outside BBH

Berkeley’s Bakar BioEnginuity Hub Opens Its Doors

“We are going to be an incredible model for the country on how to translate technologies to benefit society. Our tenant companies are solving important challenges in medicine and the environment, at the same time as creating high-value jobs,” said BBH Director David Schaffer. “In addition, we at BBH and QB3 are launching undergraduate and graduate training programs with Bakar Labs companies to help train the future workforce of California.” Read post
A cartoon of a scientist at a lab bench with a microscope and test tubes

CFF’s ‘Golden Ticket’ Competition Will Support Early Gene Research

“As part of our relentless pursuit of a cure, we are dedicated to investing in early stage science. We know that to make progress toward our bold mission to cure CF, we need to attract bold, like-minded researchers,” said Martin Mense, PhD, senior vice president of drug discovery and director of the Cystic Fibrosis Foundation Therapeutics Lab Read post
Decorative graphic with wording "Golden Ticket Competition"

Bakar Labs and the Cystic Fibrosis Foundation Support Entrepreneurs to Develop New Genetic Therapies for CF

Up to 3 selected companies will win "Golden Tickets" for lab space at Bakar Labs, and access to the extensive resources of the CF Foundation, including scientific experts and advice, lab/research tools and techniques, an extensive patient registry, clinical trial design support, and a Therapeutics Development Network of over 90 clinical trial sites in the US. Read post
Aerial view of BBH

Bakar BioEnginuity Hub Raises the Bar for Urban Adaptive Reuse Projects

“The original building structural design is kind of a house of cards,” says Allen Nudel, director of business strategy at Forell/Elsesser who led the structural team. “It’s an awe-inspiring and beautiful icon of innovation, and one of the most architecturally complicated structures in the Bay Area—maybe in the entire western United States. It was by far the most difficult seismic retrofit we’ve ever done.” Read post